© 2019 Neurana Pharmaceuticals. All Rights Reserved.

Neurana Pharmaceuticals, Inc. is a privately held biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, such as acute, painful muscle spasms of the neck and back. In May 2018, Neurana completed a $60M Series A financing led by Sofinnova Ventures and included participation from New Leaf Venture Partners, H.I.G. BioHealth, Longitude Capital and MagnaSci Ventures.

The team at Neurana Pharmaceuticals is comprised of experienced biotech executives committed to bringing a novel therapy to patients suffering from muscle spasms

President & Chief Executive Officer
Chief Financial Officer
Chief Medical Officer

DAUN BAHR – Clinical Data & Systems

CATHERINE BRISSON – Regulatory Affairs

JIM GALLAGHER – CMC, Manufacturing

JOHNNA HANNAH – Corporate Development

SANAM ARA VAUGHAN – Clinical Operations

TOM YONKER – Project Management